|
|
|
Dynavax Reports Fourth Quarter and Year End 2013 Financial Results March 10, 2014 Dynavax Announces Withdrawal of European Marketing Application for HEPLISAV(TM) February 18, 2014 Dynavax to Present at the 32nd Annual J.P. Morgan Healthcare Conference January 10, 2014 Dynavax Announces Submission of Responses to EMA Day 120 List of Questions for HEPLISAV(TM) MAA December 19, 2013 Dynavax Announces Resignation of J. Tyler Martin From Board of Directors November 27, 2013 Dynavax Reports Third Quarter 2013 Financial Results November 7, 2013 Dynavax Prices Public Offerings of Common Stock and Series B Convertible Preferred Stock October 25, 2013 Dynavax Announces Proposed Public Offerings of Common Stock and Series B Convertible Preferred Stock October 24, 2013 |
Our clinical-stage pipeline includes product candidates for the prevention and treatment of infectious diseases. More...
|
Scientific expertise and proprietary technologies drive our discovery and development of novel Toll-like Receptor (TLR) based product candidates. Our focus is on serious medical needs in the prevention and treatment of infectious diseases.
Our partnerships with leading pharmaceutical companies, including GlaxoSmithKline and AstraZeneca, and our funding agreements support our commitment to discover and develop TLR-based products to address serious medical needs.
Rhein Biotech, our European subsidiary, manufactures hepatitis B surface antigen for our lead product, HEPLISAV hepatitis B vaccine. With 20 years in business, Rhein Biotech also provides integrated product development services to enable its partners to bring products to market.
|
 |
